Utah Medical Products Inc (UTMD) — SEC Filings

Utah Medical Products Inc (UTMD) — 32 SEC filings. Latest: 8-K (May 4, 2026). Includes 13 8-K, 7 SC 13G/A, 6 10-Q.

View Utah Medical Products Inc on SEC EDGAR

Overview

Utah Medical Products Inc (UTMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: UTAH MEDICAL PRODUCTS INC (UTMD) reported a significant decline in financial performance for the three and nine months ended September 30, 2025. Net sales decreased by 1.9% to $9,812 thousand in Q3 2025 from $10,005 thousand in Q3 2024, and by 7.2% to $29,475 thousand for the nine months from $31,74

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Utah Medical Products Inc is neutral.

Filing Type Overview

Utah Medical Products Inc (UTMD) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 SC 13G, 1 DEFA14A with the SEC between Jan 2024 to May 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (32)

Utah Medical Products Inc SEC Filing History
DateFormDescriptionRisk
May 4, 20268-K8-K Filing
Nov 14, 202510-QUTMD Q3 Net Income Plunges 26% Amidst Distributor Order Cancellationshigh
Nov 4, 20258-K8-K Filing
Oct 23, 20258-KUtah Medical Products Files 8-Klow
Aug 12, 202510-QUTMD Sees Q2 Net Income Dip Amidst Revenue Declinemedium
Jul 24, 20258-KUtah Medical Products Files 8-K on Financialslow
May 15, 202510-QUtah Medical Products Inc. Files Q1 2025 10-Qlow
May 5, 20258-KUtah Medical Products Files 8-K on Shareholder Voteslow
Apr 29, 20258-KUtah Medical Products Files 8-Klow
Apr 4, 2025DEF 14AUtah Medical Products Files Definitive Proxy Statementlow
Mar 26, 202510-KUtah Medical Products Inc. Files 2024 10-Klow
Jan 28, 20258-KUtah Medical Products Files 8-Klow
Nov 12, 202410-QUtah Medical Products Inc. Files Q3 2024 10-Qlow
Nov 12, 2024SC 13G/ASC 13G/A Filing
Nov 12, 2024SC 13G/ASC 13G/A Filing
Nov 5, 20248-KUtah Medical Products Inc. Reports Leadership Changesmedium
Nov 4, 2024SC 13G/ASC 13G/A Filing
Oct 31, 2024SC 13GSC 13G Filing
Oct 29, 20248-KUtah Medical Products Files 8-K on Financialslow
Aug 9, 202410-QUtah Medical Products Inc. Q2 2024 10-Q Filingmedium

Risk Profile

Risk Assessment: Of UTMD's 22 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Utah Medical Products Inc Financial Summary (10-Q, Nov 14, 2025)
MetricValue
Revenue$9,812,000
Net Income$2,631,000
EPS$0.82
Debt-to-Equity0.03
Cash Position$84,267,000
Operating Margin26.6%
Total Assets$121,975,000
Total Debt$3,723,000

Key Executives

  • Abigail P. Johnson

Industry Context

UTMD operates in the specialty medical device market, characterized by innovation and regulatory oversight. The company's performance is sensitive to global supply chain dynamics and the purchasing decisions of international distributors, as highlighted by recent order cancellations.

Top Tags

financial-reporting (5) · 10-Q (4) · financials (3) · corporate-governance (3) · 8-k (3) · SEC Filing (3) · Financials (3) · institutional-ownership (3) · amendment (3) · medical-devices (3)

Key Numbers

Utah Medical Products Inc Key Metrics
MetricValueContext
Net Sales (Q3 2025)$9.81MDecreased by 1.9% from $10.01M in Q3 2024
Net Income (Q3 2025)$2.63MDecreased by 26.2% from $3.56M in Q3 2024
Diluted EPS (Q3 2025)$0.82Decreased by 19.9% from $1.025 in Q3 2024
Lost Revenues (Q3 2025)$581KDue to foreign distributor order cancellations
Bad Debt Expense (Q3 2025)$395KAdditional reserve for China distributor
Gross Profit Margin (Q3 2025)57.1%Reduced from 58.0% in Q3 2024 due to lower sales and absorption
Operating Income Margin (Q3 2025)26.6%Declined from 33.4% in Q3 2024
Shares Outstanding3,203,672As of November 10, 2025
Common Stock Purchased and Retired (9M 2025)$7.36MReduced from $13.26M in 9M 2024
Cash & Investments (Sept 30, 2025)$84.27MIncreased from $82.98M at Dec 31, 2024
Revenue$24.8MDecreased from $25.5M in H1 2024 to $24.8M in H1 2025, a 2.7% decline.
Net Income$4.5MDecreased from $5.1M in H1 2024 to $4.5M in H1 2025.
Revenue Decline2.7%Percentage decrease in revenue for the six months ended June 30, 2025, compared to the prior year.
Domestic Revenue$18.6MRevenue from US operations for the first half of 2025.
International Revenue$6.2MRevenue from outside US operations for the first half of 2025.

Forward-Looking Statements

  • {"claim":"FMR LLC will maintain a significant ownership stake in Utah Medical Products Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Frequently Asked Questions

What are the latest SEC filings for Utah Medical Products Inc (UTMD)?

Utah Medical Products Inc has 32 recent SEC filings from Jan 2024 to May 2026, including 13 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of UTMD filings?

Across 32 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Utah Medical Products Inc SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Utah Medical Products Inc (UTMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Utah Medical Products Inc?

Key financial highlights from Utah Medical Products Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for UTMD?

The investment thesis for UTMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Utah Medical Products Inc?

Key executives identified across Utah Medical Products Inc's filings include Abigail P. Johnson.

What are the main risk factors for Utah Medical Products Inc stock?

Of UTMD's 22 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Utah Medical Products Inc?

Recent forward-looking statements from Utah Medical Products Inc include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Utah Medical Products Inc. for the foreseeable future.".

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.